

CLEARBRIDGE HEALTH LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 201001436C)

**FURTHER UPDATE ON CIVIL SUIT FILED BY A JOINT VENTURE PARTNER
OF AN INDIRECT SUBSIDIARY IN INDONESIA**

The Board of Directors of Clearbridge Health Limited (the "**Company**") and together with its subsidiaries, the "**Group**") refers to the announcements dated 31 May 2020, 23 August 2020, 8 June 2021, 6 August 2021 and 4 August 2022 (collectively, the "**Announcements**") relating to the civil suit (the "**Suit**") filed by PT Tirta Medika Nusantara ("**TMN**"), an existing shareholder of the Company's indirect subsidiary, PT Tirta Medika Jaya ("**TMJ**"), against, among others, (1) Clearbridge Medical Asia Pte. Ltd., a wholly-owned subsidiary of the Company ("**CBMA**"), and (2) TMJ. Unless otherwise defined, capitalised terms in this announcement shall have the same meaning as ascribed to them in the Announcements.

Further to Jakarta High Court's decision (the "**Court's Decision**") that the Suit be returned to and heard in the North Jakarta District Court, the Group wishes to announce that on 16 August 2022, CBMA filed a notice of appeal to the Indonesia Supreme Court against the whole of the Court's Decision (the "**Appeal**"). As of the date of this announcement, a hearing date for the appeal has not been fixed. In addition, CBMA has been advised by its Indonesian legal counsel that if the Appeal succeeds, the Supreme Court will uphold the decision of the North Jakarta District Court that the North Jakarta District Court does not in fact have jurisdiction to hear the Suit.

Presently, the operations at TMJ and CBMA are unaffected by the Appeal.

Moving forward, the Suit and the Appeal will have no material impact on the financial performance and condition of the Group for the current financial year ending 31 December 2022 ("**FY2022**") if the Appeal and the Suit is decided, in FY2022, in favour of CBMA and/or TMJ.

By contrast, the Suit and the Appeal may have a material adverse impact on the financial performance and condition of the Group for FY2022 if the Appeal and the Suit is decided, in FY2022, in favour of TMN. As set out in the Company's announcement on 31 May 2020, TMN is seeking, among others, (a) the North Jakarta District Court's declaration that a certain notarial deed has been made unlawfully and consequently, (b) damages of IDR 1.06 trillion (approximately SGD 99 million¹) to be paid. No substantiation has been provided by TMN on how this claim for IDR 1.06 trillion has been derived.

The Group is unable to comment further on the probability of the outcome of the Appeal and the Suit at this juncture. The Group and its legal advisors will update its shareholders if there are any further material developments on this matter.

¹ Based on an exchange rate of S\$1.00: IDR10,711 as at 16 August 2022 published by the Monetary Authority of Singapore.

Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants, or other professional advisers if they are in doubt about the actions that they should take.

BY ORDER OF THE BOARD

YEE PINH JEREMY

Executive Director and Chief Executive Officer

16 August 2022

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalyst. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*